Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Sci Rep ; 14(1): 10632, 2024 05 09.
Artigo em Inglês | MEDLINE | ID: mdl-38724585

RESUMO

While some clinics have adopted abbreviated neoadjuvant treatment for HER2-positive breast cancer, there remains a shortage of comprehensive clinical data to support this practice. This is a retrospective, multicenter study. A total of 142 patients were included in the study who are HER2-positive breast cancer, aged ≤ 65 years, with left ventricular ejection fraction ≥ 50%, received neoadjuvant chemotherapy and underwent surgery at 10 different oncology centers in Türkiye between October 2016 and December 2022. The treatment arms were divided into 4-6 cycles of docetaxel/trastuzumab/pertuzumab for arm A, 4 cycles of adriamycin/cyclophosphamide followed by 4 cycles of taxane/TP for arm B. There were 50 patients (35.2%) in arm A and 92 patients (64.8%) in arm B. The median follow-up of all of the patients was 19.9 months (95% CI 17.5-22.3). The 3-year DFS rates for treatment arms A and B were 90.0% and 83.8%, respectively, and the survival outcomes between the groups were similar (p = 0.34). Furthermore, the pathologic complete response rates were similar in both treatment arms, at 50.0% and 51.1%, respectively (p = 0.90). This study supports shortened neoadjuvant treatment of HER2-positive breast cancer, a common practice in some clinics.


Assuntos
Antraciclinas , Protocolos de Quimioterapia Combinada Antineoplásica , Neoplasias da Mama , Terapia Neoadjuvante , Receptor ErbB-2 , Trastuzumab , Humanos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Neoplasias da Mama/mortalidade , Feminino , Pessoa de Meia-Idade , Terapia Neoadjuvante/métodos , Receptor ErbB-2/metabolismo , Antraciclinas/uso terapêutico , Antraciclinas/administração & dosagem , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Estudos Retrospectivos , Trastuzumab/uso terapêutico , Ciclofosfamida/uso terapêutico , Ciclofosfamida/administração & dosagem , Docetaxel/uso terapêutico , Docetaxel/administração & dosagem , Taxoides/uso terapêutico , Taxoides/administração & dosagem , Doxorrubicina/uso terapêutico , Doxorrubicina/administração & dosagem , Hidrocarbonetos Aromáticos com Pontes/uso terapêutico , Hidrocarbonetos Aromáticos com Pontes/administração & dosagem , Resultado do Tratamento , Idoso , Anticorpos Monoclonais Humanizados
2.
Onkologie ; 35(10): 576-80, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23038228

RESUMO

BACKGROUND: We retrospectively evaluated the efficacy and toxicity of paclitaxel plus doxorubicin as a second-line treatment in patients with urothelial carcinoma, who had not responded to a prior platinum plus gemcitabine combination. PATIENTS AND METHODS: All patients received intravenous infusions of paclitaxel (175 mg/m(2)/h) and doxorubicin (50 mg/m(2)/30 min) on day 1. Chemotherapy courses were repeated every 21 days. RESULTS: The median followup duration was 13.5 months (range 2.8-22.4 months). Complete and partial responses were observed in 2 (5.6%) and 10 (27.8%) patients, respectively. Median overall survival was 8.9 months (95% confidence interval (CI): 6.2-11.6). Median time to progression was 3.8 months (95% CI: 2.7-4.8). The most common hematologic toxicities were neutropenia (n = 21, 58.3%), thrombocytopenia (n = 10, 27.8%), and anemia (n = 9, 25%). The most common nonhematologic toxicities consisted of fatigue (n = 15, 41.7%), nausea/vomiting (n = 13, 36.1%), peripheral neuropathy (n = 11, 30.6%), and mucositis (n = 6, 16.7%). Dose reductions by 25-35% were performed in 6 (16.7%) patients because of grade 3/4 toxicity. Anthracycline-related heart failure did not occur. CONCLUSION: 3-weekly courses of cyclic paclitaxel plus doxorubicin were found to be effective and tolerable in patients with urothelial carcinoma, who had not responded to prior platinum- and gemcitabine-based chemotherapy.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Carcinoma de Células de Transição/tratamento farmacológico , Pré-Medicação/métodos , Neoplasias da Bexiga Urinária/tratamento farmacológico , Adolescente , Adulto , Idoso , Carcinoma de Células de Transição/diagnóstico , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Doxorrubicina/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Paclitaxel/administração & dosagem , Platina/administração & dosagem , Estudos Retrospectivos , Resultado do Tratamento , Neoplasias da Bexiga Urinária/diagnóstico , Adulto Jovem , Gencitabina
3.
Onkologie ; 32(7): 417-9, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19556820

RESUMO

BACKGROUND: Gestational trophoblastic disease occurs rarely in postmenopausal women. CASE REPORT: We report on a 65-year-old woman with uterine choriocarcinoma developing 16 years after menopause and 25 years after her last pregnancy. She was found to have a uterine tumor on laparotomy after presenting with uterine bleeding and abdominal pain. Histopathological examination demonstrated malignant syncytiotrophoblastic and cytotrophoblastic cells with extensive necrosis and hemorrhage, consistent with pure choriocarcinoma. Chemotherapy consisting of etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine (EMA-CO) was started. The treatment was changed to methotrexate and folinic acid because of severe hypersensitivity reaction after etoposide infusion. After 4 cycles, the serum beta-human chorionic gonadotropin (beta-hCG) level had decreased to normal. The patient remains disease free 20 months after the treatment. CONCLUSIONS: This case further illustrates that choriocarcinoma may be seen in older women after a long menopausal period. Accurate diagnosis and treatment are essential, because the tumor is very chemosensitive and curable even in advanced stages.


Assuntos
Coriocarcinoma não Gestacional/diagnóstico , Pós-Menopausa , Neoplasias Uterinas/diagnóstico , Idoso , Feminino , Humanos , Doenças Raras/diagnóstico
4.
Med Princ Pract ; 18(1): 76-80, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19060498

RESUMO

OBJECTIVES: To report a case of metastatic leiomyosarcoma, in which a patient developed chest pain accompanied by acute left bundle-branch block (LBBB) after gemcitabine infusion. CLINICAL PRESENTATION AND INTERVENTION: A 59-year-old woman admitted with bilateral pulmonary nodules had classic risk factors for coronary heart disease and coronary stenosis as demonstrated by previous coronary angiography. She was treated with gemcitabine infusion, and 30 min later she experienced severe chest pain accompanied by acute LBBB confirmed by ECG. We suspected gemcitabine-induced coronary vasospasm exacerbated by the preexisting coronary artery disease as the cause of the acute coronary syndrome. The patient was subsequently treated with antianginal therapy and percutaneous coronary intervention. Her chest pain resolved and LBBB disappeared. She was discharged 2 days later without any further cardiac events. No additional cancer therapy was given and she died 5 months later, due to disease progression. CONCLUSION: This case showed that chemotherapeutic agents must be administered with intensive cardiac monitoring especially in patients with cardiac disease and well-known risk factors to prevent the development of cardiac complications, despite an agent not being known to be 'cardiotoxic'.


Assuntos
Antimetabólitos Antineoplásicos/efeitos adversos , Bloqueio de Ramo/induzido quimicamente , Doença da Artéria Coronariana/complicações , Desoxicitidina/análogos & derivados , Aspirina/uso terapêutico , Bloqueio de Ramo/diagnóstico , Bloqueio de Ramo/tratamento farmacológico , Clopidogrel , Vasoespasmo Coronário/induzido quimicamente , Desoxicitidina/efeitos adversos , Eletrocardiografia , Evolução Fatal , Feminino , Humanos , Leiomiossarcoma , Neoplasias Pulmonares/secundário , Pessoa de Meia-Idade , Inibidores da Agregação Plaquetária/uso terapêutico , Fatores de Risco , Ticlopidina/análogos & derivados , Ticlopidina/uso terapêutico , Gencitabina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA